Godavari Drugs Limited (BOM:530317)
77.27
+1.67 (2.21%)
At close: Mar 5, 2026
Godavari Drugs Revenue
Godavari Drugs had revenue of 222.01M INR in the quarter ending December 31, 2025, a decrease of -25.12%. This brings the company's revenue in the last twelve months to 986.94M, down -22.20% year-over-year. In the fiscal year ending March 31, 2025, Godavari Drugs had annual revenue of 1.14B, down -27.42%.
Revenue (ttm)
986.94M
Revenue Growth
-22.20%
P/S Ratio
0.59
Revenue / Employee
9.31M
Employees
106
Market Cap
581.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.14B | -431.17M | -27.42% |
| Mar 31, 2024 | 1.57B | -24.03M | -1.51% |
| Mar 31, 2023 | 1.60B | -16.37M | -1.01% |
| Mar 31, 2022 | 1.61B | 384.48M | 31.31% |
| Mar 31, 2021 | 1.23B | 270.62M | 28.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mangalam Drugs & Organics | 2.38B |
| Accretion Pharmaceuticals | 826.43M |
| Walpar Nutritions | 757.46M |
| Onyx Biotec | 663.87M |
| Shelter Pharma | 598.96M |
| Panjon | 493.34M |
| Rajnish Wellness | 455.79M |
| Phaarmasia | 449.06M |